Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
about
Are the effects of a non-drug multimodal activation therapy of dementia sustainable? Follow-up study 10 months after completion of a randomised controlled trialCholinesterase inhibitors for Alzheimer's diseaseWithdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementiaRivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 yearsRational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysisPersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsLong-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care PhysicianLongitudinal medication usage in Alzheimer disease patients.Can you have dementia with an MMSE score of 30?Donepezil: a clinical review of current and emerging indications.Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.Methods to improve the detection of mild cognitive impairmentEfficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies.Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristicsEfficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.Errorless practice as a possible adjuvant to donepezil in Alzheimer's disease.New concepts in the drug therapy of Alzheimer's disease.Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Presenile dementia syndromes: an update on taxonomy and diagnosis.Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsLong-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process.Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.Clinically tested drugs for Alzheimer's disease.Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.Positron emission tomography scans obtained for the evaluation of cognitive dysfunction.Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.Cholinergic modulation of working memory activity in primate prefrontal cortex.Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease.Practical Principles for the Management of Alzheimer's Disease.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease.OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.Alzheimer's disease: the benefits of early treatment.Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.Recognition and treatment of Alzheimer's disease: a case-based review.Donepezil: a review.
P2860
Q21261392-B6343221-CE7A-49A2-8701-B0686EED94DDQ22252975-FFF543F5-73D3-4E99-9475-A4A86F483FEFQ24235324-6CFCA11D-B0FA-4B03-9374-FD76C69DD3ECQ24800075-5B995F05-A3C7-49E9-9DDE-789BDD672473Q24805169-57C2B291-C2FC-4872-89DF-698F19610A2FQ26997299-06F754DE-F92D-426B-81D1-4BB4AA83DBB2Q30433785-CAC7B21D-B859-4F3E-A785-D8FB82A114F5Q30549920-07679DD3-2874-46BD-A6CE-DA6540167F19Q31134210-66FD25BE-4BCD-42B3-9104-7F31A93BA76AQ33150809-CB029318-3B42-47D5-A20C-AC4D89AA6E0EQ33662471-E28D4B7A-F172-43F8-A7F8-114D81344891Q33933152-820CB999-76EE-4CAC-84F9-9BC9147C9785Q34128361-C09C8BD8-CD85-4188-A85B-FD74E2C118AAQ34153726-1B406B0B-640B-4CE2-B3C6-5314540353C1Q34156798-F08B9FC8-5CFF-4059-880D-E60DC8CD4A56Q34181037-7424BA13-FB91-423C-B12D-5DC5B09B07C2Q34301111-201A77F9-AE1A-44B3-819D-C97F52A6C34BQ34334170-1D188183-1D2B-474C-BBAA-C6C850D422DFQ34443767-C088F347-F28F-46AD-AC77-601242D58C99Q34515565-33EA071E-1408-4826-A7F3-6116A3E6635EQ34648742-A29BDC26-57A8-45FE-9E59-4070DB4C2A4AQ34649249-B7670247-FF49-4A9A-A589-6E9A80F81B99Q34965949-2F11123D-96F3-48EA-A406-B4C27DCB4DBEQ35006354-1CFBC9C5-D39E-4A50-AB1E-92BF4B082DACQ35058123-7079A443-878E-42E6-BE31-B4D6BB1814D1Q35112092-BA4B3FFA-8D77-42FA-B4C6-00EE099FD38BQ35164747-7153673C-7DA2-4796-A645-2DC4132C61EBQ35327053-30B938A4-9539-4732-8984-A2817CCF0DB6Q35446894-A4414C94-7337-478C-932C-5A8ECAD8D9CDQ35465836-07975E0F-B12E-4661-8DAA-461E5DD9A040Q35543969-98B5CA33-AA69-4DE9-BD01-037F5536AE53Q35606762-208F0F3E-434E-41D9-BE29-91BAEBB1FC35Q35667052-8A40591B-A1E8-4889-86A5-7715E46AEAF8Q35876403-DE31A08D-2840-40B1-9AC1-A39759C9BA94Q36142354-66CB51F7-075A-4970-A6A8-F91EA02464D6Q36221014-3C2774A4-AD21-42F8-850D-BB0C5669D0AAQ36249975-AF6CDAC0-4338-4753-9B07-DC3537F290FBQ36401406-1847523B-2CEB-46A3-AD5F-88082D6937FCQ36458308-95D28985-9B13-47FB-A2AF-CDF4CDEF3B9EQ36544994-D7075199-C502-4458-A0F6-63F3B1CCEC64
P2860
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Open-label, multicenter, phase ...... tients with Alzheimer disease.
@en
Open-label, multicenter, phase ...... tients with Alzheimer disease.
@nl
type
label
Open-label, multicenter, phase ...... tients with Alzheimer disease.
@en
Open-label, multicenter, phase ...... tients with Alzheimer disease.
@nl
prefLabel
Open-label, multicenter, phase ...... tients with Alzheimer disease.
@en
Open-label, multicenter, phase ...... tients with Alzheimer disease.
@nl
P2093
P1433
P1476
Open-label, multicenter, phase ...... tients with Alzheimer disease.
@en
P2093
C A Perdomo
D S Geldmacher
Donepezil Study Group
P304
P356
10.1001/ARCHNEUR.58.3.427
P577
2001-03-01T00:00:00Z